Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2

Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2

Epidemiological and mechanistic studies suggest that some US Food and Drug Administration (FDA)-approved drugs can reduce the incidence of cancer and inhibit tumor growth. Therefore, investigating FDA-approved drugs for cancer chemoprevention is a promising strategy. In this study, we screened FDA-a...

Full description

Bibliographic Details
Main Authors: Lili Zhao, Yuhan Zhang, Ang Li, Xuebo Lu, Mingzhu Li, Qiang Yuan, Ning Yang, Xiaokun Zhao, Xin Li, Yanan Jiang, Kangdong Liu
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
esophageal squamous cell carcinoma
azelnidipine
proliferation
cell cycle
MEK1/2 inhibitor
MEK1/2-ERK1/2 signaling pathway
Online Access:http://www.sciencedirect.com/science/article/pii/S237277052200119X

Internet

http://www.sciencedirect.com/science/article/pii/S237277052200119X

Similar Items